Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02772588 · ClinicalTrials.gov registry record · Phase 2
AASUR in High Risk Prostate Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02772588: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02772588 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02772588, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether anti-testosterone medications, when administered before, during, and after high-dose, precision radiation, will be effective in preventing the prostate cancer from returning.
Interventions
- DRUG Abiraterone
- DRUG Leuprolide
- DRUG ARN-509
- RADIATION stereotactic, ultra-fractionated radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-05-12 |
| Est. Completion | 2026-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02772588
The ClinicalTrials.gov registry entry for NCT02772588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Abiraterone is the first listed.
NCT02772588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02772588 about?
NCT02772588 is a clinical study titled "AASUR in High Risk Prostate Cancer". The purpose of this study is to determine whether anti-testosterone medications, when administered before, during, and after high-dose, precision radiation, will be effective in preventing the prostate cancer from returning.
What is the current status of trial NCT02772588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2016-05-12. Estimated completion is 2026-01-22.
What interventions are being tested in trial NCT02772588?
The interventions under investigation include: Abiraterone (DRUG), Leuprolide (DRUG), ARN-509 (DRUG), stereotactic, ultra-fractionated radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02772588?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.